Preemptive Pharmacogenomic Testing Versus Reactive Genotyping Improves Effectiveness and Lowers Costs

Physicians often test patients when a reaction to medicine occurs, but what if there is testing to see how well a patient will metabolize medicine before they take it? The field of pharmacogenomics can often determine this information before starting a new medicine and can save critical care time and the cost of medicines that don’t work well. A recent journal article examines the differences between preemptive pharmacogenomic testing versus reactive genotyping in a variety of patients.

Leave a Comment

Your email address will not be published. Required fields are marked *